Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer.

These findings underscore the potential of immune tumor microenvironment features for identifying patients with MMRd EC and primary resistance to ICI who should be oriented towards trials testing novel immunotherapeutic combinations.